biobucks

Lantheus pledges up to $2B for 2 of POINT's radiopharmaceuticals

Lantheus is paying $260 million upfront for a double bill of licenses for two of POINT Biopharma’s radiopharmaceutical oncology candidates.

James Waldron Nov 14, 2022 9:50am

Ionis, Metagenomi pen Big Pharma-sized pact worth up to $3B

Nov 14, 2022 6:50am

Insilico strikes gold with Sanofi deal worth up to $1.2B

Nov 8, 2022 9:00am

Busy day for Exelixis with 2 new deals worth $937M+ in biobucks

Nov 1, 2022 7:20pm

Bayer's Vividion pens $930M biobucks pact with Tavros

Oct 12, 2022 7:30am

Sanofi wagers $400M in biobucks to go after muscular dystrophy

Oct 4, 2022 8:00am